Are there alternative treatments to Rifaximin (Rifamycin) for Small Intestine Bacterial Overgrowth (SIBO)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Yes, there are several alternative treatments to rifaximin for Small Intestinal Bacterial Overgrowth (SIBO), including other antibiotics such as metronidazole, amoxicillin-clavulanate, doxycycline, and norfloxacine, as well as non-absorbable antibiotics like neomycin. According to the most recent and highest quality study 1, sequential antibiotic therapy is very effective in treating intestinal bacterial overgrowth and reducing malabsorption. The study suggests that alternating cycles with metronidazole and tetracycline may be necessary to limit resistance.

Some key points to consider when choosing an alternative treatment to rifaximin include:

  • The type of SIBO: methane-dominant SIBO may respond better to certain antibiotics like neomycin
  • Previous treatment response: patients who have not responded to rifaximin may benefit from a different antibiotic or combination therapy
  • Individual tolerance to medications: patients with certain medical conditions or taking certain medications may need to avoid certain antibiotics

Other alternatives to rifaximin include:

  • Herbal antimicrobials like oregano oil, berberine, and allicin from garlic, which have antimicrobial properties and can be effective in reducing SIBO symptoms
  • Elemental diets, which provide pre-digested nutrients that are absorbed in the upper small intestine and can effectively starve the bacteria
  • Prokinetic agents like low-dose erythromycin, prucalopride, or motegrity, which can help prevent SIBO recurrence by improving intestinal motility. As noted in 1, octreotide can also be used to reduce secretions and slow gastrointestinal motility in refractory SIBO.

It's worth noting that while probiotics have been suggested as a potential therapeutic intervention for SIBO, there is currently limited evidence to support their use, as noted in 1 and 1. However, further research is needed to fully understand the role of probiotics in the treatment of SIBO.

From the Research

Alternative Treatments for SIBO

There are alternative treatments to rifaximin for helping to treat Small Intestinal Bacterial Overgrowth (SIBO). Some of these alternatives include:

  • Metronidazole: a study comparing rifaximin and metronidazole found that rifaximin had a higher SIBO decontamination rate and was better tolerated 2
  • Other antibiotics: although rifaximin is often preferred due to its targeted action on the gut and lower risk of resistance, other antibiotics may be used in certain cases
  • Non-antibiotic treatments: some studies suggest that non-antibiotic treatments, such as dietary changes or probiotics, may be effective in managing SIBO symptoms, although more research is needed to confirm this

Comparison of Rifaximin with Other Treatments

Studies have compared the efficacy of rifaximin with other treatments for SIBO, including:

  • Metronidazole: rifaximin was found to have a higher eradication rate and be better tolerated than metronidazole 2
  • Placebo or active controls: a meta-analysis found no significant difference in efficacy between rifaximin and placebo or active controls, although subgroup analysis suggested a dose-dependent effect of rifaximin 3

Efficacy of Alternative Treatments

The efficacy of alternative treatments for SIBO is not as well established as that of rifaximin. However, some studies suggest that:

  • Metronidazole may be effective in eradicating SIBO, although it may have a lower success rate than rifaximin 2
  • Other antibiotics may also be effective, although more research is needed to confirm this
  • Non-antibiotic treatments, such as dietary changes or probiotics, may be effective in managing SIBO symptoms, although more research is needed to confirm this 4, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole.

European review for medical and pharmacological sciences, 2009

Research

Review of rifaximin as treatment for SIBO and IBS.

Expert opinion on investigational drugs, 2009

Research

Preferential usage of rifaximin for the treatment of hydrogen-positive smallintestinal bacterial overgrowth.

Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru, 2019

Related Questions

What are treatment options for Small Intestine Bacterial Overgrowth (SIBO) other than Xifaxan (Rifaximin)?
What is the treatment for Small Intestine Bacterial Overgrowth (SIBO)?
What are the treatment options for Small Intestine Bacterial Overgrowth (SIBO)?
Can Cipro (ciprofloxacin) be used to treat Small Intestine Bacterial Overgrowth (SIBO)?
What to do about fatigue and a feeling of floatiness after starting allicin and rifaximin (Xifaxan) for Small Intestine Bacterial Overgrowth (SIBO)?
What are the antibiotic treatment options for colitis (inflammation of the colon)?
What is the role of oral calcium supplementation in treating hypocalcemia (low calcium levels)?
What is the diagnosis for a fluid-filled cyst on the underside of the glans penis?
Can you perform an analysis with the following diagnoses?
What is the diagnosis for a 66-year-old male with elevated total Triiodothyronine (T3) at 3.27, elevated free T3 at 4.7, normal Thyroid-Stimulating Hormone (TSH) at 2.01, elevated total Thyroxine (T4) at 5.9, and normal free T4 at 1.26?
What is the management approach for a patient with Chronic Obstructive Pulmonary Disease (COPD) Anthonisen type II, Medical Research Council (MRC) grade 2, and CAT score of 21, exacerbated by community-acquired pneumonia, with a CURB-65 score of 2 and PSI (Pneumonia Severity Index) score of 108, and comorbidities including type 2 Diabetes Mellitus, systemic arterial Hypertension, grade III normocytic hypochromic Anemia according to the World Health Organization (WHO), FRAIL (Fatigue, Resistance, Ambulation, Illness, and Loss of weight) score of 4, high risk of pressure ulcers, and normal nutritional status?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.